Steve Aydin, DO
Interventional Pain Medicine · Franklin Lakes, NJNPI 1104099910
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Vertos Medical, Inc. accounts for 60.5% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2023 at $6,748 and has fallen 93.8% since, to $415 in 2025. Among interventional pain medicine clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $66.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertos Medical, Inc.$13K
- Pfizer$3K
- Stryker$947
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$857
- Amgen$723
- Johnson & Johnson$484
- plus $3K from 39 others
What the payments were for
- Consulting fees$11,63853%
- Speaking & faculty fees$3,40716%
- Travel & lodging$8414%
- Food & beverage$6,03228%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- mild Device Kit$11,978
- RELISTOR$857
- Intracept$737
- Superion ISS$229
- IVS - VERTEBRAL AUGMENTATION PRODUCTS$126
- EVENITY$125
How this compares
$21,918 in reported general payments places this provider in the 90th percentile of 82 interventional pain medicine providers in New Jersey.
See all interventional pain medicine providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 238 | $6,711 |
| Tizanidine Hcl | 191 | $2,038 |
| Gabapentin | 92 | $988 |
| Cyclobenzaprine Hcl | 34 | $374 |
| Meloxicam | 104 | $252 |
| Tramadol Hcl | 35 | $230 |
| Pregabalin | 12 | $121 |
| Prednisone | 44 | $82 |
| Amoxicillin | 18 | $27 |
| Diazepam | 14 | $21 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Franklin Lakes
- Youssef JosephsonWest Deptford$496K
- Ali ValimahomedHolmdel$415K
- Saurabh DangEdgewater$157K
- Gabriele JasperBrick$114K
- Matthew LippChatham$67K
- Didier DemesminSomerset$33K
- Kieran SlevinHainesport$21K
- John CoccaroToms River$17K
- Dinash YanamadulaLawrenceville$16K
- Jay ShahColonia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.